Option Care Health, Inc. filings document the public-company disclosures of a Nasdaq-listed provider of home and alternate-site infusion services. Its common stock is registered under the symbol OPCH, and its regulatory record includes Current Reports on Form 8-K, proxy materials, and exhibits tied to operating results and corporate actions.
OPCH filings cover quarterly and annual financial results, non-GAAP measure reconciliations, Regulation FD investor presentations, amendments to its first lien credit agreement, executive officer changes and related severance matters, and definitive proxy disclosures. The proxy record addresses board governance, stockholder voting matters, executive compensation, and capital allocation context for the company's infusion services business.
Option Care Health, Inc. reported third-quarter 2026 revenue of $1,493.5 million, up 4.1% from a year earlier, and net income of $57.4 million, up 10.8%. Gross profit was $285.0 million; nine-month operating cash flow was $286.2 million, compared with $222.6 million in 2025. Acute therapy growth contributed to revenue gains, while chronic inflammatory disease (CID) declines tied to patient attrition and therapy mix remained a headwind.
Management expects CID-related dynamics to negatively affect 2026 gross profit by approximately $55 million. During the first nine months, the company repurchased 7,880,038 shares for $167.5 million at an average price of $21.26 per share; no shares were repurchased in the third quarter.
Under an agreement entered October 5, 2026, an investor group comprising certain affiliates of Clayton, Dubilier & Rice, LLC and McKesson Corporation is to acquire the company. Each outstanding common share, subject to specified exceptions, would convert into a right to receive $32.05 in cash without interest, subject to stockholder and regulatory approvals and other closing conditions. The deal is expected to close in the first half of 2027; completion would make the company private and end its public-market listing.
Option Care Health, Inc. reported third-quarter 2026 net revenue of $1,493.5 million, up 4.1% year over year. GAAP net income was $57.4 million, up 10.8%, and GAAP diluted earnings per share were $0.38, up 18.8%. Adjusted EBITDA was $124.6 million, up 4.3%, and adjusted diluted earnings per share were $0.49, up 8.9%. Cash provided by operating activities in the quarter was $114.7 million.
For the nine months ended September 30, 2026, net cash provided by operating activities was $286.212 million, versus $222.556 million for the nine months ended September 30, 2025. Cash and cash equivalents were $299.093 million as of September 30, 2026, compared with $232.624 million as of December 31, 2025. Long-term debt, net of discount, deferred financing costs and current portion, was $1,151.054 million as of September 30, 2026, versus $1,154.052 million as of December 31, 2025.
Option Care Health said it had entered into a definitive merger agreement under which it will be acquired by Clayton, Dubilier & Rice, LLC and McKesson Corporation. Given the pending acquisition, it withdrew previously disclosed financial guidance and will not host an earnings conference call for these results. Adjusted EBITDA and adjusted diluted EPS are non-GAAP measures; reconciliations to comparable GAAP measures were provided.
Option Care Health, Inc. (OPCH) agreed to merge with Onyx Merger Sub, Inc., which will merge into Option Care Health, leaving the company as a wholly owned subsidiary of Onyx Bidco LLC. If completed, each eligible share of OPCH common stock will convert into the right to receive $32.05 in cash, without interest. Company- or Parent-owned shares will be cancelled without consideration; holders who properly perfect appraisal rights may seek fair value under Delaware law. The board unanimously approved the agreement and recommends votes FOR the merger, advisory compensation and adjournment proposals.
Completion requires approval by holders of a majority of outstanding shares entitled to vote, regulatory approvals and other closing conditions. Parent estimates approximately $5.8 billion in total funds will be needed and expects financing to combine up to $3,150,000,000 in committed loans, up to $500 million in revolving credit commitments, and $2,873,295,853 in equity commitments. Option Care Health currently expects closing in the first half of calendar year 2027, pending regulatory approvals and the stockholder vote. Upon completion, OPCH shares will be delisted from Nasdaq.
BlackRock, Inc. reported beneficial ownership of 19,587,246 shares of Option Care Health, Inc. common stock, or 13.1% of the class, as of September 30, 2026. The reported position reflects securities beneficially owned or deemed beneficially owned by certain BlackRock business units, subsidiaries and affiliates, excluding business units whose ownership is disaggregated. BlackRock reported sole voting power over 19,143,612 shares and sole dispositive power over 19,587,246 shares, with no shared voting or dispositive power.
Option Care Health, Inc. (OPCH) agreed to be acquired by an investor group comprising affiliates of Clayton, Dubilier & Rice (CD&R) and McKesson for $32.05 in cash per share, subject to stockholder and regulatory approvals and other closing conditions. The stated enterprise value is approximately $5.8 billion; the price represents an approximately 37% premium to OPCH’s October 5, 2026 closing share price. Holders who properly exercise appraisal rights are entitled to fair value under Delaware law, subject to those rights being preserved.
After closing, CD&R is expected to hold approximately 51% and McKesson approximately 49%; McKesson’s announced investment is approximately $1.4 billion. Closing is expected in the first half of calendar 2027, after which OPCH would be privately held and its common stock no longer publicly listed. OPCH expects to release third-quarter results on November 4, 2026, will not host a live earnings call, and withdrew its previously disclosed 2026 financial guidance.
Durable Capital Partners filed an amended ownership report on Option Care Health, Inc. common stock. Durable Capital Master Fund LP directly holds 6,163,722 shares, and Durable Capital Partners, as investment adviser, has sole power to vote and dispose of these shares. This position represents 3.9% of Option Care Health’s common stock, based on 157,027,504 shares outstanding as of April 28, 2026. The filing notes that the economic benefits of the shares are shared among related parties under existing agreements.
Option Care Health delivered modest growth in the first half of 2026. For Q2, net revenue rose 1.9% to $1.44 billion, while gross margin slipped to 18.5% from 19.0% as therapy mix shifted. Net income increased 6.7% to $53.9 million, with diluted EPS of $0.35.
For the first six months, revenue reached $2.79 billion and net income $99.3 million. Operating cash flow strengthened sharply to $171.5 million, helped by a significant inventory reduction. The company invested $20.1 million in capital expenditures and did not close any acquisitions in 2026 to date.
Leverage remains meaningful, with total debt principal of $1.17 billion, but liquidity is supported by $193.8 million of cash and $846.0 million of available Revolver capacity. The company repurchased 7.9 million shares for $167.5 million in the first half, leaving $525.0 million authorized. Management highlights ongoing pressure in its chronic inflammatory disease portfolio and expects CID dynamics to reduce 2026 gross profit by about $55 million, partially offset by growth in acute and other higher-margin therapies.
Option Care Health, Inc. reported second quarter 2026 net revenue of $1,442 million, up 1.9% year over year. GAAP net income was $53.9 million and diluted EPS $0.35, increases of 6.7% and 12.9%. Adjusted EBITDA rose 3.0% to $117.5 million and adjusted diluted EPS grew 9.8% to $0.45.
Operating cash generation increased, with $184 million provided by operating activities in Q2 and $171.5 million in the first half of 2026, compared with $83.1 million a year earlier. The company repurchased $150 million of shares in the quarter. As of June 30, 2026, total assets were $3.38 billion, long-term debt was $1.15 billion and stockholders’ equity was $1.26 billion.
For full-year 2026, Option Care Health expects net revenue of $5.675–$5.775 billion, adjusted EBITDA of $480–$495 million, adjusted diluted EPS of $1.85–$1.92 and at least $320 million of operating cash flow. For third quarter 2026, it anticipates sequential low- to mid-single-digit growth in net revenue and mid-single-digit growth in adjusted EBITDA.
Bhatia Prateek reported acquisition or exercise transactions in this Form 4 filing.
Option Care Health, Inc. executive vice president Prateek Bhatia reported receiving two stock awards of common stock as equity compensation. One award covered 23,409 shares, after which that line of ownership shows 39,795 shares directly held. A second award covered 16,386 shares, with that line showing 16,386 shares directly held after the grant.
The awards are in the form of restricted stock units that vest in stages. According to the filing, one third of the underlying shares vest on each of the first, second, and third anniversaries of the grant date, tying the compensation to continued service over three years.
Option Care Health, Inc. executive Prateek Bhatia, who serves as Executive Vice President, Sp Sales & Solutions, has filed an initial ownership report on Form 3 as an officer of the company. The filing does not report any stock purchases, sales, option exercises, or other transactions.